Currently, the only approved pharmacological therapy for ischemic stroke is recombinant tissue plasminogen activator (tPA; Alberts and Naidech, 2013) but the effect of tPA is limited by a narrow therapeutic window (<4.5 h; Fang et al., 2010). This evidence concerns the gene PLAT and ischemic stroke.